Bacteria surviving within leukocytes are protected from the lethal action of high concentrations of most antibiotics, which may explain, in part, the failure of bactericidal antibiotics to eradicate staphylococci from abscesses. Since rifampin is unique in its ability to kill intraleukocytic bacteria, the efficacy of this drug was tested in the treatment of staphylococcal infections in mice. Groups of mice infected intravenously with Staphylococcus aureus were treated with rifampin (20 mg/kg), procaine penicillin (937.5 mg/kg), or methicillin (200 mg/kg). All untreated mice died with disseminated visceral abscesses. After 10 days of therapy, survival in groups treated with penicillin and methicillin was 16 and 20%, respec-tively, whereas with rifampin it was 80% (P < 0.0005). Antibiotic concentrations in the serum of mice treated with penicillin, methicillin, or rifampin were bactericidal for the strain of S. aureus used. Serial bacterial counts of kidney, lung, and spleen homogenates showed that neither penicillin nor methicillin was able to eradicate staphylococci, whereas rifampin completely sterilized those organs in many mice. When abscess contents and infected peritoneal washings were incubated with high concentrations of penicillin, methicillin, or rifampin, only rifampin killed all of the bacteria. The capacity of rifampin to eradicate staphylococci from pus in vitro and from abscesses in mice appears to be related to the ability of rifampin to kill intraleukocytic bacteria.
Staphylococcus aureus can survive the intraleukocytic environment after being phagocytized by polymorphonuclear neutrophils (PMN; 12). Several investigators (1, 7, 13) have shown that bacteria surviving within phagocytes are protected from the lethal actions of high concentrations of most antibiotics. In vitro studies with 10 bactericidal antibiotics (11) showed that only rifampin was able to kill intraleukocytic staphylococci.
Rifampin is a semisynthetic antibiotic derivative of rifamycin B, with a fairly broad antibacterial spectrum (3, 8, 9) and potent antistaphylococcal activity (2) . It has also been demonstrated in vitro that rifampin does not interfere with phagocytosis and bactericidal activity of PMN (6) .
The present studies were undertaken to determine whether rifampin could eradicate staphylococci from abscesses or influence mortality in an experimental staphylococcal infection in mice. MATERIALS Each sample of leukocyte suspension was divided into three 1-ml portions. Rifampin (10 lg) was added to one, penicillin (100 units) was added to another, and no antibiotic was added to the third sample. The tubes were then agitated with a vortex mixer and tumbled end over end for 18 hr at 37 C. At the end of this time, the tubes were iced and centrifuged at 200 X g for 5 min. The supernatant fluid was decanted, and serial dilutions and pour-plate cultures were done to obtain viable bacterial counts. The sediment was washed with saline to remove antibiotics and was resuspended and agitated in distilled water to lyse the leukocytes. The number of viable sediment-associated bacteria was determined by serial dilution and pour-plate techniques.
RESULTS
As shown in Fig. 1 , there were no survivors among untreated mice by 16 days after infection with staphylococci. Only 16% of mice treated with penicillin and 20% of mice treated with methicillin survived for 30 days after infection. In marked contrast, treatment with rifampin resulted in 80% survival (P < 0.0005).
Serial bacterial counts of kidney, lung, and spleen showed that rifampin-treated animals had significantly lower tissue bacterial counts and more sterile organs (Fig. 2-4) .
The Wood 46 strain of S. aureus was susceptible to the antibiotics used in these experiments. The MBC for penicillin, methicillin, and rifampin was 0.098 units/ml (0.059 Mg/ml), 3 .13 g/lml, and 0.195 ,ug/ml, respectively. Antibiotic concentrations attained in serum were bactericidal (Fig. 5) for at least part of the day with all three antibiotics.
Only rifampin sterilized pus or peritoneal washings after an overnight incubation, but rifampin, penicillin, and methicillin killed all of the staphylococci in the supernatant fluid (extracellular organisms; Fig. 6 and 7) . All three antibiotics lost activity when incubated with infected peritoneal exudate. After 18 hr, 100 Mg of methicillin activity/ml decreased to 6.8 Mg/ml, 100 units of penicillin activity/ml dropped to 53 units/ml, and 100 ug of rifampin activity/ml fell to 60 MAg/ml. This ability of rifampin to eradicate bacteria in vivo correlates with its ability to sterilize peritoneal exudates and pus, and to kill intraleukocytic bacteria. The ability of rifampin to penetrate phagocytic membranes and kill ingested organisms may well be the explanation for its marked efficacy in vivo.
DISCUSSION
The problem of the emergence of rifampinresistant strains has been discussed by Kunin et al. (8) , but resistance to rifampin was not encountered in the present studies.
These observations suggest that rifampin has a place in the treatment of deep-seated infections associated with abscess formation when surgical in 6 I_ on October 11, 2017 by guest http://aac.asm.org/ Downloaded from drainage is not feasible. Another area where rifampin may be useful is in the treatment of patients whose leukocytes are unable to kill ingested bacteria normally (i.e., patients with chronic granulomatous disease of childhood or Chediak-Higashi syndrome). In these situations, rifampin probably should be used with another antibiotic to minimize the development of resistant strains.
